Alnylam Suspends Fitusiran Dosing due to Thrombotic Event
The Company has suspended dosing in all ongoing fitusiran studies pending further review of the safety event and development of a risk mitigation strategy.
Alnylam Suspends Fitusiran Dosing due to Thrombotic Event Read More »
